ScinoPharm is among the global leaders in the development and manufacture of high-quality active pharmaceutical ingredients (API). The company supports drug development and manufacturing with a full range of API services from process development, production of early phase clinical trial material to large-scale manufacuring for commercial launches.
Headquartered in Taiwan, ScinoPharm operates a cGMP facility in full compliance with regulatory standards of US, EU, Japan, Australia, Korea, etc. Out of the 18 manufacturing lines, 6 are capable of handling high potency, cytotoxic compounds including many injectable oncological APIs.
While we are continuing to expand our Taiwan facility, we are also expanding in China, with the
construction of our R&D center and a new large grass-roots API plant in the Changshu Economic and Technological Development Zone of Jiangsu Province, and the expansion of our marketing operations in Shanghai. This growing footprint allows us to actively work with members of the Chinese pharmaceutical community to develop new business opportunities.
With research and manufacturing facilities in both Taiwan and Mainland China, ScinoPharm offers a wide portfolio of services ranging from custom synthesis for early phase pharmaceutical activities to brand companies as well as APIs for the generic industry. The Company also provides a vertically integrated, one-stop-shopping service for its API customers by expanding into the field of oncological injectable formulation.